Home/Filings/4/0000882104-18-000104
4//SEC Filing

Stone Christopher Lewis 4

Accession 0000882104-18-000104

CIK 0000882104other

Filed

Sep 26, 8:00 PM ET

Accepted

Sep 27, 4:41 PM ET

Size

5.6 KB

Accession

0000882104-18-000104

Insider Transaction Report

Form 4
Period: 2018-09-25
Stone Christopher Lewis
VP and General Counsel
Transactions
  • Award

    Stock Option (right to buy)

    2018-09-25+339,623339,623 total
    Exercise: $2.52Exp: 2028-09-25Common stock (339,623 underlying)
Footnotes (1)
  • [F1]The stock options will vest on a monthly basis pro rata over the 48 months following January 1, 2018, provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employment provided in the severance agreement between the issuer and the recipient.

Issuer

PDL BIOPHARMA, INC.

CIK 0000882104

Entity typeother

Related Parties

1
  • filerCIK 0001453373

Filing Metadata

Form type
4
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 4:41 PM ET
Size
5.6 KB